Episode Details:
Join us on the latest episode, hosted by Jared S. Taylor!
Our Guest: Peter Donnelly, CEO & Co-Founder at Genomics.
What you’ll get out of this episode:
- Genomics’ Mission: Founded in 2014, Genomics is bridging cutting-edge genetic research with real-world healthcare solutions.
- Actionable Insights: Advances now allow actionable health insights for ~70% of people via genetic testing.
- Strategic Partnerships: Collaborations with companies like Vertex and GSK use genetics to improve drug targeting and trial outcomes.
- Insurance Innovation: Life insurers are early adopters of genetics to promote longevity and healthier lives.
- The Future Is Now: With global health systems under pressure, predictive genomics is primed to shift care from treatment to prevention.
Watch
Listen
Read More
Sir Peter Donnelly, a Rhodes Scholar and former academic leader in genetics, transitioned from Oxford’s research halls to the forefront of biotech. As CEO and Co-Founder of Genomics, he brings decades of scientific experience into transforming how we understand and use DNA to manage health.
From Rare Diseases to Common Risks
Historically, genetic testing could only identify serious, rare conditions in a small percentage of the population. Now, with the evolution of science, Genomics can assess risk for common diseases—like heart disease, diabetes, and cancer—in over 70% of healthy adults. This seismic shift enables earlier and more personalized prevention strategies.
A Data-Driven Platform with a Global Edge
Genomics has developed one of the world’s largest genetic data resources. Their proprietary algorithms help pharmaceutical companies identify new drug targets and validate existing ones, increasing the likelihood of successful clinical trials. With software-as-a-service solutions, Genomics empowers partners across biotech, pharma, and insurance industries.
Prevention: The Missing Link in Modern Healthcare
Donnelly champions a “shift left” in healthcare—from reactive treatments to proactive prevention. By identifying individuals’ genetic predispositions, health systems can tailor screenings and interventions, improving outcomes and efficiency. A standout example is Genomics’ work with life insurers, using genetic risk to support longer, healthier lives without influencing eligibility.
Why Now Is the Moment
Healthcare systems face rising costs and inefficiencies. Genomics offers a timely solution: a scientifically validated, ready-to-scale technology that makes predicting and preventing disease not just possible, but practical. As more individuals gain access to genetic insights, this approach will become embedded in standard healthcare practices.
Looking Ahead
Donnelly envisions a future where genetic data is a core component of health records, used not only for disease prevention but also for tailoring treatments, guiding procedures, and supporting medication adherence. The era of truly personalized medicine is within reach.
Finally, to learn more about our guest and their company please use the links below:
– Company LinkedIn – Company Website –
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter –
